Zevra Therapeutics (ZVRA) Cash & Equivalents Growth (1y) (2015 - 2026)

Zevra Therapeutics (ZVRA) Cash & Equivalents Growth (1y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 23.81%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 15.53%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 90.42%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 17.50%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -4.13%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 71.81%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Zevra Therapeutics 570.04 Mn 369.43 Mn 34.32 Mn 156.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 156.01%
Dec 31, 2025 84.72%
Sep 30, 2025 0.74%
Jun 30, 2025 21.53%
Mar 31, 2025 -12.86%
Dec 31, 2024 -21.52%
Sep 30, 2024 24.89%
Mar 31, 2024 6.64%
Dec 31, 2023 -34.24%
Sep 30, 2023 -38.24%
Dec 31, 2022 -41.73%
Sep 30, 2022 -46.72%
Jun 30, 2022 -41.96%
Dec 31, 2021 2,566.65%
Sep 30, 2021 2,396.73%
Jun 30, 2021 1,977.17%
Mar 31, 2021 3,122.28%
Dec 31, 2020 30.96%
Sep 30, 2020 -19.19%
Jun 30, 2020 -12.85%